Jan Raupach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Raupach has a total of 295 co-authors. Here are the top co-authors by number of shared publications:
- Antonín Krajina
Department of Radiology, Faculty of Medicine in Hradec Kralove Charles University Prague Czech Republic
17 shared publications Miroslav Lojik
Department of Radiology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
9 shared publications- Igor Gunka
Department of Surgery, University Hospital and Faculty of Medicine Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
8 shared publications - Ondrej Renc
Department of Radiology, Faculty of Medicine in Hradec Králové, Charles University, 500 03 Hradec Králové, Czech Republic
8 shared publications Vendelin Chovanec
Department of Radiology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
7 shared publications- Alexander Ferko
Department of Surgery, Charles University and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
6 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047192
Large Core Stroke Thrombectomy Is Safe and Effective Regardless of Prior Antithrombotic or Thrombolytic Treatment: A Secondary Analysis of the Randomized TENSION Trial
Background: The relevance of prior antithrombotic and thrombolytic treatment for decision‐making regarding endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion with established large infarcts is uncertain. This study investigates associations of prior antithrombotic medication and thrombolysis with the efficacy and safety of EVT for acute ischemic stroke due to large vessel occlusion with established large infarct. Methods: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a prospective randomized open‐label blinded–end point clinical trial. Patients with acute ischemic stroke due to large vessel occlusion and established large infarct were randomized to EVT with medical therapy or medical therapy alone. Exposures were preadmission antithrombotic treatment with antiplatelet agents or anticoagulants and intravenous thrombolysis. The primary efficacy end point was functional outcome at 90 days. Safety outcomes included death and symptomatic intracranial hemorrhage. Results: The study included 246 patients (median age, 74 years; interquartile range, 65 to 80 years; 49% women); 124 (50%) were assigned to EVT. Of 176 patients (72%) with prior antithrombotic therapy, 75 (31%) received antiplatelets, 56 (23%) anticoagulants, and 89 (36%) intravenous thrombolysis. EVT was associated with better functional outcome in patients with (common odds ratio [cOR], 2.40 [95% CI, 1.22–4.99]) and without (cOR, 2.29 [95% CI, 1.53–3.46]) antiplatelet therapy; with (cOR, 2.45 [95% CI, 1.17–5.28]) and without (cOR, 2.12 [95% CI, 1.44–3.15]) anticoagulation; as well as receiving (cOR, 1.46 [95% CI, 0.83–2.61]) and not receiving (cOR, 2.89 [95% CI, 1.87–4.51]) thrombolysis. Interaction analyses were consistent with similar treatment effects across subgroups. Mortality and rates of symptomatic intracranial hemorrhage were similar between groups. Conclusions: Benefit and safety of EVT were not modified by prior antithrombotic/thrombolytic therapy. Preadmission exposure to antiplatelets or anticoagulants or use of intravenous thrombolysis should not exclude eligible patients with stroke from EVT. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03094715.
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047192
Open AccessLarge Core Stroke Thrombectomy Is Safe and Effective Regardless of Prior Antithrombotic or Thrombolytic Treatment: A Secondary Analysis of the Randomized TENSION Trial
Background: The relevance of prior antithrombotic and thrombolytic treatment for decision‐making regarding endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion with established large infarcts is uncertain. This study investigates associations of prior antithrombotic medication and thrombolysis with the efficacy and safety of EVT for acute ischemic stroke due to large vessel occlusion with established large infarct. Methods: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a prospective randomized open‐label blinded–end point clinical trial. Patients with acute ischemic stroke due to large vessel occlusion and established large infarct were randomized to EVT with medical therapy or medical therapy alone. Exposures were preadmission antithrombotic treatment with antiplatelet agents or anticoagulants and intravenous thrombolysis. The primary efficacy end point was functional outcome at 90 days. Safety outcomes included death and symptomatic intracranial hemorrhage. Results: The study included 246 patients (median age, 74 years; interquartile range, 65 to 80 years; 49% women); 124 (50%) were assigned to EVT. Of 176 patients (72%) with prior antithrombotic therapy, 75 (31%) received antiplatelets, 56 (23%) anticoagulants, and 89 (36%) intravenous thrombolysis. EVT was associated with better functional outcome in patients with (common odds ratio [cOR], 2.40 [95% CI, 1.22–4.99]) and without (cOR, 2.29 [95% CI, 1.53–3.46]) antiplatelet therapy; with (cOR, 2.45 [95% CI, 1.17–5.28]) and without (cOR, 2.12 [95% CI, 1.44–3.15]) anticoagulation; as well as receiving (cOR, 1.46 [95% CI, 0.83–2.61]) and not receiving (cOR, 2.89 [95% CI, 1.87–4.51]) thrombolysis. Interaction analyses were consistent with similar treatment effects across subgroups. Mortality and rates of symptomatic intracranial hemorrhage were similar between groups. Conclusions: Benefit and safety of EVT were not modified by prior antithrombotic/thrombolytic therapy. Preadmission exposure to antiplatelets or anticoagulants or use of intravenous thrombolysis should not exclude eligible patients with stroke from EVT. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03094715.
- Open Access
- 29 May 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1)
Cerebral DWI lesion burden following carotid artery stenting with guided antiplatelet therapy: a retrospective comparative study
Purpose: To analyze the number, location, and clinical significance of new ischemic lesions (NIL) after carotid stenting in patients with guided antiplatelet therapy. To evaluate factors leading to thromboembolic complications and silent ischemia. Secondarily, we compared the incidence of NIL among historical cohorts with guided and standard antiplatelet therapy. Methods: We conducted a retrospective analysis of prospectively collected data from 171 patients who underwent carotid stenting in a single center between 2014 and 2023. Magnetic resonance imaging with diffusion-weighted images was performed before and after stenting. We evaluated NIL after the procedure and their dependence on patient demographics, degree of stenosis, instrumentation used, and antiplatelet therapy. The incidence of NIL was compared to three cohorts receiving more potent or guided antiplatelet therapy based on platelet function test ( n = 689) and to seven cohorts receiving standard dual antiplatelet therapy with aspirin and clopidogrel ( n = 2777), using the meta-analytical approach. Results: New ischemic lesions were found in 15.8% of patients (27/171). We recorded five ischemic strokes (2.9%). Most NIL were located in the ipsilateral middle cerebral artery basin (91%), but they also occurred contralaterally or in another basin. Stenosis length ≥ 15 mm ( p = 0.012) was shown to be significantly associated with the development of NIL. The incidence of NIL in a center with guided antiplatelet therapy was distinctly lower compared to results of the studies with standard antiplatelet therapy, 15.8% vs. 28.3–51.3%. Conclusion: Guided antiplatelet therapy in carotid stenting is safe and shows a lower incidence of new ischemic lesions on MR-DWI compared to results with standard antiplatelet therapy. In this study with guided antiplatelet therapy, NIL were only associated with greater stenosis length.
- 29 May 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1)
Open AccessCerebral DWI lesion burden following carotid artery stenting with guided antiplatelet therapy: a retrospective comparative study
Purpose: To analyze the number, location, and clinical significance of new ischemic lesions (NIL) after carotid stenting in patients with guided antiplatelet therapy. To evaluate factors leading to thromboembolic complications and silent ischemia. Secondarily, we compared the incidence of NIL among historical cohorts with guided and standard antiplatelet therapy. Methods: We conducted a retrospective analysis of prospectively collected data from 171 patients who underwent carotid stenting in a single center between 2014 and 2023. Magnetic resonance imaging with diffusion-weighted images was performed before and after stenting. We evaluated NIL after the procedure and their dependence on patient demographics, degree of stenosis, instrumentation used, and antiplatelet therapy. The incidence of NIL was compared to three cohorts receiving more potent or guided antiplatelet therapy based on platelet function test ( n = 689) and to seven cohorts receiving standard dual antiplatelet therapy with aspirin and clopidogrel ( n = 2777), using the meta-analytical approach. Results: New ischemic lesions were found in 15.8% of patients (27/171). We recorded five ischemic strokes (2.9%). Most NIL were located in the ipsilateral middle cerebral artery basin (91%), but they also occurred contralaterally or in another basin. Stenosis length ≥ 15 mm ( p = 0.012) was shown to be significantly associated with the development of NIL. The incidence of NIL in a center with guided antiplatelet therapy was distinctly lower compared to results of the studies with standard antiplatelet therapy, 15.8% vs. 28.3–51.3%. Conclusion: Guided antiplatelet therapy in carotid stenting is safe and shows a lower incidence of new ischemic lesions on MR-DWI compared to results with standard antiplatelet therapy. In this study with guided antiplatelet therapy, NIL were only associated with greater stenosis length.
- Open Access
- 10 February 2026
- Published by MDPI AG in Clinics and Practice
- Vol. 16 (2) , 38
Overcoming Clopidogrel Resistance in Carotid Artery Stenting: Experience with Ticagrelor and Ticlopidine
Objectives: The goal of this study is to establish the incidence of high on-treatment platelet reactivity (HTPR) to aspirin and clopidogrel in patients undergoing carotid stenting and to evaluate the efficacy of ticagrelor and ticlopidine in patients with HTPR to clopidogrel. Methods: In a single institutional setting spanning eight years, every consecutive patient who underwent carotid artery stenting was incorporated into a study. Subsequently, a retrospective analysis of their platelet function was executed. Prevalence of high on-treatment reactivity to aspirin, clopidogrel, ticlopidine and ticagrelor was assessed. Platelet function testing was conducted by light transmission aggregometry and Multiplate®. Results: A total of 216 patients were tested for antiplatelet therapy efficacy. The high on-treatment reactivity to clopidogrel was observed in 68 patients (31.4%). No patients with high on-treatment reactivity to ticagrelor or ticlopidine were observed. There was a significant reduction in platelet reactivity with ticagrelor (p < 0.000) and ticlopidine (p < 0.000) in patients with HTPR to clopidogrel. Conclusions: High on-treatment platelet reactivity to clopidogrel is common in patients undergoing carotid artery stenting. Ticagrelor is a viable alternative to overcome HTPR to clopidogrel. These findings suggest that platelet function testing can identify patients who may benefit from tailored antiplatelet therapy in reducing thromboembolic complications after carotid stenting.
- 10 February 2026
- Published by MDPI AG in Clinics and Practice
- Vol. 16 (2) , 38
Open AccessOvercoming Clopidogrel Resistance in Carotid Artery Stenting: Experience with Ticagrelor and Ticlopidine
Objectives: The goal of this study is to establish the incidence of high on-treatment platelet reactivity (HTPR) to aspirin and clopidogrel in patients undergoing carotid stenting and to evaluate the efficacy of ticagrelor and ticlopidine in patients with HTPR to clopidogrel. Methods: In a single institutional setting spanning eight years, every consecutive patient who underwent carotid artery stenting was incorporated into a study. Subsequently, a retrospective analysis of their platelet function was executed. Prevalence of high on-treatment reactivity to aspirin, clopidogrel, ticlopidine and ticagrelor was assessed. Platelet function testing was conducted by light transmission aggregometry and Multiplate®. Results: A total of 216 patients were tested for antiplatelet therapy efficacy. The high on-treatment reactivity to clopidogrel was observed in 68 patients (31.4%). No patients with high on-treatment reactivity to ticagrelor or ticlopidine were observed. There was a significant reduction in platelet reactivity with ticagrelor (p < 0.000) and ticlopidine (p < 0.000) in patients with HTPR to clopidogrel. Conclusions: High on-treatment platelet reactivity to clopidogrel is common in patients undergoing carotid artery stenting. Ticagrelor is a viable alternative to overcome HTPR to clopidogrel. These findings suggest that platelet function testing can identify patients who may benefit from tailored antiplatelet therapy in reducing thromboembolic complications after carotid stenting.
- Open Access
- 10 December 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (5) , 646-656
Reperfusion-dependent treatment effects of thrombectomy in patients with large ischemic infarcts
Background: While thrombectomy benefits patients with large infarcts, it is unclear whether this benefit persists across different levels of reperfusion. Aims: This study investigates how the degree of reperfusion influences the effectiveness of endovascular thrombectomy (EVT) combined with best medical treatment (BMT), compared to BMT alone, in patients with large infarcts. Methods: This post hoc analysis of the TENSION trial, a randomized controlled study, assessed EVT versus BMT in patients with extensive infarction (Alberta Stroke Program Early CT Score (ASPECTS) 3–5). Primary outcome was the modified Rankin Scale (mRS) score at 90 days. Secondary outcomes included infarct volume at 24 h, mortality, and symptomatic hemorrhage. Outcomes were stratified by final reperfusion level, measured with the modified thrombolysis in cerebral infarction (mTICI) scale. Confounder-adjusted common odds ratios (cORs) and average treatment effects (ATEs) were estimated using inverse probability weighting with regression adjustment. Results: A total of 246 patients (median age, 74 years (interquartile range (IQR), 65–80); median baseline ASPECTS, 4 (IQR, 3–5)) were included. Compared to BMT alone, unsuccessful EVT (mTICI ⩽ 2a) was not associated with worse functional outcomes (cOR:1.2, 95% CI, 0.95 to 1.52; p = 0.131), higher mortality (ATE: –11.6%; 95% CI, –28.82 to 5.61; p = 0.187), or larger infarct volumes on follow-up (ATE:0.99 mL; 95% CI, –45.30 to 45.32; p = 0.965). First-pass complete reperfusion (mTICI 3) showed the greatest treatment benefit, significantly improving all endpoints, with a cOR of 4.85 (95% CI, 3.74–6.31; p < 0.001) for improved mRS scores and a 29% absolute reduction in mortality. Conclusion: In this post hoc analysis of the TENSION trial, unsuccessful EVT did not worsen outcomes compared to BMT alone. The highest benefit of EVT occurred with first-pass complete reperfusion, emphasizing the importance of achieving optimal reperfusion in this vulnerable stroke subgroup. These findings do not justify general treatment recommendations.
- 10 December 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (5) , 646-656
Open AccessReperfusion-dependent treatment effects of thrombectomy in patients with large ischemic infarcts
Background: While thrombectomy benefits patients with large infarcts, it is unclear whether this benefit persists across different levels of reperfusion. Aims: This study investigates how the degree of reperfusion influences the effectiveness of endovascular thrombectomy (EVT) combined with best medical treatment (BMT), compared to BMT alone, in patients with large infarcts. Methods: This post hoc analysis of the TENSION trial, a randomized controlled study, assessed EVT versus BMT in patients with extensive infarction (Alberta Stroke Program Early CT Score (ASPECTS) 3–5). Primary outcome was the modified Rankin Scale (mRS) score at 90 days. Secondary outcomes included infarct volume at 24 h, mortality, and symptomatic hemorrhage. Outcomes were stratified by final reperfusion level, measured with the modified thrombolysis in cerebral infarction (mTICI) scale. Confounder-adjusted common odds ratios (cORs) and average treatment effects (ATEs) were estimated using inverse probability weighting with regression adjustment. Results: A total of 246 patients (median age, 74 years (interquartile range (IQR), 65–80); median baseline ASPECTS, 4 (IQR, 3–5)) were included. Compared to BMT alone, unsuccessful EVT (mTICI ⩽ 2a) was not associated with worse functional outcomes (cOR:1.2, 95% CI, 0.95 to 1.52; p = 0.131), higher mortality (ATE: –11.6%; 95% CI, –28.82 to 5.61; p = 0.187), or larger infarct volumes on follow-up (ATE:0.99 mL; 95% CI, –45.30 to 45.32; p = 0.965). First-pass complete reperfusion (mTICI 3) showed the greatest treatment benefit, significantly improving all endpoints, with a cOR of 4.85 (95% CI, 3.74–6.31; p < 0.001) for improved mRS scores and a 29% absolute reduction in mortality. Conclusion: In this post hoc analysis of the TENSION trial, unsuccessful EVT did not worsen outcomes compared to BMT alone. The highest benefit of EVT occurred with first-pass complete reperfusion, emphasizing the importance of achieving optimal reperfusion in this vulnerable stroke subgroup. These findings do not justify general treatment recommendations.
- 1 May 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (5) , 1116-1127
Thrombectomy With Low ASPECTS: The Roles of Infarct Volume and Postacute Neurological Status
BACKGROUND: Recent randomized trials demonstrated the beneficial effect of endovascular therapy in patients with low Alberta Stroke Program Early CT Score. Despite large follow-up infarct volumes, a significantly increased rate of good functional outcomes was observed, challenging the role of infarct volume as a predictive imaging marker. This analysis evaluates the extent to which the effects of endovascular thrombectomy on functional outcomes are explained by (1) follow-up infarct volume and (2) early neurological status in patients with stroke with low Alberta Stroke Program Early CT Score. METHODS: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a randomized trial conducted from February 2018 to January 2023 across 41 stroke centers. Two hundred fifty-three patients with ischemic stroke due to anterior circulation large vessel occlusion and Alberta Stroke Program Early CT Score of 3 to 5 were randomized to endovascular thrombectomy plus medical treatment or medical treatment alone. All patients with the availability of relevant data points were included in this secondary as-treated analysis. The primary outcome was the 90-day modified Rankin Scale score. Confounder-adjusted mediation analysis was performed to quantify the proportion of the treatment effect on a 90-day modified Rankin Scale score explained by (1) 24-hour follow-up infarct volume and (2) 24-hour National Institutes of Health Stroke Scale scores. RESULTS: One hundred eighty-eight patients were included; thereof, 87 (46%) were female patients. Median age was 72 (interquartile range, 63–79) years. The endovascular thrombectomy cohort had a 20.5 (95% CI, 8.3–33.7) percentage points higher probability of achieving independent ambulation (modified Rankin Scale, 0–3) and a 24.2 (95% CI, 13.4–35.8) percentage points lower mortality at 90 days compared with medical treatment alone. The reduction in 24-hour follow-up infarct volume explained 30% of the treatment effect on functional outcomes, while the 24-hour National Institutes of Health Stroke Scale score explained 61%. CONCLUSIONS: In patients with low Alberta Stroke Program Early CT Score, infarct volume demonstrated limited explanatory power for functional outcomes compared with the early neurological status, which may more effectively reflect factors such as the involvement of specific brain regions, disruption of structural networks, and selective neuronal loss.
- 1 May 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (5) , 1116-1127
Thrombectomy With Low ASPECTS: The Roles of Infarct Volume and Postacute Neurological Status
BACKGROUND: Recent randomized trials demonstrated the beneficial effect of endovascular therapy in patients with low Alberta Stroke Program Early CT Score. Despite large follow-up infarct volumes, a significantly increased rate of good functional outcomes was observed, challenging the role of infarct volume as a predictive imaging marker. This analysis evaluates the extent to which the effects of endovascular thrombectomy on functional outcomes are explained by (1) follow-up infarct volume and (2) early neurological status in patients with stroke with low Alberta Stroke Program Early CT Score. METHODS: TENSION (Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window) was a randomized trial conducted from February 2018 to January 2023 across 41 stroke centers. Two hundred fifty-three patients with ischemic stroke due to anterior circulation large vessel occlusion and Alberta Stroke Program Early CT Score of 3 to 5 were randomized to endovascular thrombectomy plus medical treatment or medical treatment alone. All patients with the availability of relevant data points were included in this secondary as-treated analysis. The primary outcome was the 90-day modified Rankin Scale score. Confounder-adjusted mediation analysis was performed to quantify the proportion of the treatment effect on a 90-day modified Rankin Scale score explained by (1) 24-hour follow-up infarct volume and (2) 24-hour National Institutes of Health Stroke Scale scores. RESULTS: One hundred eighty-eight patients were included; thereof, 87 (46%) were female patients. Median age was 72 (interquartile range, 63–79) years. The endovascular thrombectomy cohort had a 20.5 (95% CI, 8.3–33.7) percentage points higher probability of achieving independent ambulation (modified Rankin Scale, 0–3) and a 24.2 (95% CI, 13.4–35.8) percentage points lower mortality at 90 days compared with medical treatment alone. The reduction in 24-hour follow-up infarct volume explained 30% of the treatment effect on functional outcomes, while the 24-hour National Institutes of Health Stroke Scale score explained 61%. CONCLUSIONS: In patients with low Alberta Stroke Program Early CT Score, infarct volume demonstrated limited explanatory power for functional outcomes compared with the early neurological status, which may more effectively reflect factors such as the involvement of specific brain regions, disruption of structural networks, and selective neuronal loss.
- Open Access
- 9 October 2024
- Published by Springer Nature in CVIR Endovascular
- Vol. 7 (1) , 1-10
Outcome of tailored antiplatelet therapy in carotid stenting: a retrospective comparative study
Background: Carotid stenting requires dual antiplatelet therapy to effectively prevent thromboembolic complications. However, resistance to clopidogrel, a key component of this therapy, may lead to persistent risk of these complications. The aim of this study was to determine, if the implementation of routine platelet function testing and adjusting therapy was associated with lower incidence of thromboembolic complications and death. Methods: All consecutive patients treated with carotid artery stenting in a single institution over 8 years were enlisted in a retrospective study. Platelet function testing was performed, and efficient antiplatelet therapy was set before the procedure. Incidence of procedure-related stroke or death within periprocedural period (0–30 days) was assessed. The results were evaluated in relation to the findings of six prominent randomized control trials. Results: A total of 241 patients were treated for carotid stenosis, seven patients undergo CAS on both sides over time. There was 138 symptomatic (55,6%) and 110 asymptomatic stenoses (44,4%). Five thromboembolic complications (2,01%) occurred, four of them (1,61%) was procedure-related. Two patients died because of procedure-related stroke (0,82%). Incidence of procedure-related stroke or death was significant lower compared to the results of CREST study (2,01% vs. 4,81%, P = 0,0243) in the entire cohorts, and to the results of ICSS study in the symptomatic cohorts (2,86% vs. 7,37%, P = 0,0243), respectively. Conclusions: Tailored antiplatelet therapy in carotid stenting is safe and seems to be related with lower incidence of procedure-related death or stroke rate. Larger prospective studies to assess whether platelet function testing-guided antiplatelet therapy is superior to standard dual antiplatelet should be considered.
- 9 October 2024
- Published by Springer Nature in CVIR Endovascular
- Vol. 7 (1) , 1-10
Open AccessOutcome of tailored antiplatelet therapy in carotid stenting: a retrospective comparative study
Background: Carotid stenting requires dual antiplatelet therapy to effectively prevent thromboembolic complications. However, resistance to clopidogrel, a key component of this therapy, may lead to persistent risk of these complications. The aim of this study was to determine, if the implementation of routine platelet function testing and adjusting therapy was associated with lower incidence of thromboembolic complications and death. Methods: All consecutive patients treated with carotid artery stenting in a single institution over 8 years were enlisted in a retrospective study. Platelet function testing was performed, and efficient antiplatelet therapy was set before the procedure. Incidence of procedure-related stroke or death within periprocedural period (0–30 days) was assessed. The results were evaluated in relation to the findings of six prominent randomized control trials. Results: A total of 241 patients were treated for carotid stenosis, seven patients undergo CAS on both sides over time. There was 138 symptomatic (55,6%) and 110 asymptomatic stenoses (44,4%). Five thromboembolic complications (2,01%) occurred, four of them (1,61%) was procedure-related. Two patients died because of procedure-related stroke (0,82%). Incidence of procedure-related stroke or death was significant lower compared to the results of CREST study (2,01% vs. 4,81%, P = 0,0243) in the entire cohorts, and to the results of ICSS study in the symptomatic cohorts (2,86% vs. 7,37%, P = 0,0243), respectively. Conclusions: Tailored antiplatelet therapy in carotid stenting is safe and seems to be related with lower incidence of procedure-related death or stroke rate. Larger prospective studies to assess whether platelet function testing-guided antiplatelet therapy is superior to standard dual antiplatelet should be considered.
- Open Access
- 9 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4010
Percutaneous Transluminal Angioplasty for Atherosclerotic Stenosis of Vertebral Artery Origin
Background: In patients with vertebral artery origin (VAO) stenosis and concomitant stenoses of other cerebral feeding arteries, data on the risk of percutaneous transluminal angioplasty (PTA) alone and with stent placement (PTAS) for VAO stenosis are limited. We aimed to determine how the presence of polystenotic lesions in other cerebral feeding arteries and concomitant carotid artery stenting (CAS) affect the periprocedural risk and long-term effect of PTA/S for atherosclerotic VAO stenosis. Methods: In a retrospective descriptive study, consecutive patients treated with PTA/S for ≥70% VAO stenosis were divided into groups with isolated VAO stenosis and multiple stenoses. We investigated the rate of periprocedural complications in the first 72 h and the risk of restenosis and ischemic stroke (IS)/transient ischemic attack (TIA) during the follow-up period. Results: In a set of 66 patients aged 66.1 ± 9.1 years, polystenotic lesions were present in 56 (84.8%) patients. 21 (31.8%) patients underwent endovascular treatment for stenosis of one or more other arteries in addition to VAO stenosis (15 underwent CAS). During the periprocedural period, no patient suffered from an IS or died, and, in the polystenotic group with concomitant CAS, there was one case of TIA (1.6%). During a mean follow-up period of 36 months, we identified 8 cases (16.3%) of ≥50% asymptomatic VA restenosis, and, in the polystenotic group, 4 (8.9%) cases of IS. Conclusion: The presence of severe polystenotic lesions or concomitant CAS had no adverse effect on the overall low periprocedural risk of PTA/S of VAO stenosis or the risk of restenosis during the follow-up period.
- 9 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4010
Open AccessPercutaneous Transluminal Angioplasty for Atherosclerotic Stenosis of Vertebral Artery Origin
Background: In patients with vertebral artery origin (VAO) stenosis and concomitant stenoses of other cerebral feeding arteries, data on the risk of percutaneous transluminal angioplasty (PTA) alone and with stent placement (PTAS) for VAO stenosis are limited. We aimed to determine how the presence of polystenotic lesions in other cerebral feeding arteries and concomitant carotid artery stenting (CAS) affect the periprocedural risk and long-term effect of PTA/S for atherosclerotic VAO stenosis. Methods: In a retrospective descriptive study, consecutive patients treated with PTA/S for ≥70% VAO stenosis were divided into groups with isolated VAO stenosis and multiple stenoses. We investigated the rate of periprocedural complications in the first 72 h and the risk of restenosis and ischemic stroke (IS)/transient ischemic attack (TIA) during the follow-up period. Results: In a set of 66 patients aged 66.1 ± 9.1 years, polystenotic lesions were present in 56 (84.8%) patients. 21 (31.8%) patients underwent endovascular treatment for stenosis of one or more other arteries in addition to VAO stenosis (15 underwent CAS). During the periprocedural period, no patient suffered from an IS or died, and, in the polystenotic group with concomitant CAS, there was one case of TIA (1.6%). During a mean follow-up period of 36 months, we identified 8 cases (16.3%) of ≥50% asymptomatic VA restenosis, and, in the polystenotic group, 4 (8.9%) cases of IS. Conclusion: The presence of severe polystenotic lesions or concomitant CAS had no adverse effect on the overall low periprocedural risk of PTA/S of VAO stenosis or the risk of restenosis during the follow-up period.
- Open Access
- 5 July 2023
- Published by Springer Nature in CVIR Endovascular
- Vol. 6 (1) , 1-4
Complex endoleak treatment after failed endovascular aortic repair
Background: Endovascular aneurysm repair (EVAR) has created new possibilities for patients with abdominal aortic aneurysms (AAAs), and in recent years it has become tremendously popular. Use of EVAR in selected groups of patients allows mortality and morbidity to be reduced in comparison to open repair. However, complications such as endoleaks (ELs) can be of great concern and warrant urgent therapy to prevent sac rupture. Case presentation: The case report presents urgent endovascular treatment of a high-risk type IA EL in a polymorbid 68-year-old patient 7 years after primary EVAR. The principle of treatment was parallel implantation of the proximal SG extension with the renal SG into the right renal artery (chimney technique). The subsequent type II collateral EL was treated by direct transabdominal AAA sac puncture and thrombin embolization. Conclusion: EL can be a cause for urgent intervention, but specific anatomic features often require specialized SG types which are not readily available. The chimney technique allows the use of immediately available stent grafts to address endoleak in the setting of impending abdominal aneurysm rupture.
- 5 July 2023
- Published by Springer Nature in CVIR Endovascular
- Vol. 6 (1) , 1-4
Open AccessComplex endoleak treatment after failed endovascular aortic repair
Background: Endovascular aneurysm repair (EVAR) has created new possibilities for patients with abdominal aortic aneurysms (AAAs), and in recent years it has become tremendously popular. Use of EVAR in selected groups of patients allows mortality and morbidity to be reduced in comparison to open repair. However, complications such as endoleaks (ELs) can be of great concern and warrant urgent therapy to prevent sac rupture. Case presentation: The case report presents urgent endovascular treatment of a high-risk type IA EL in a polymorbid 68-year-old patient 7 years after primary EVAR. The principle of treatment was parallel implantation of the proximal SG extension with the renal SG into the right renal artery (chimney technique). The subsequent type II collateral EL was treated by direct transabdominal AAA sac puncture and thrombin embolization. Conclusion: EL can be a cause for urgent intervention, but specific anatomic features often require specialized SG types which are not readily available. The chimney technique allows the use of immediately available stent grafts to address endoleak in the setting of impending abdominal aneurysm rupture.
- Open Access
- 4 April 2023
- Published by Springer Nature in Research Square
Complex Endoleak Treatment After Failed Endovascular Aortic Repair
Background Endovascular aneurysm repair (EVAR) has created new possibilities for patients with abdominal aortic aneurysms (AAAs), and in recent years it has become tremendously popular. Use of EVAR in selected groups of patients allows mortality and morbidity to be reduced in comparison to open repair. However, complications such as endoleaks (ELs) can be of great concern and warrant urgent therapy to prevent sac rupture. Case Presentation The case report presents urgent endovascular treatment of a high-risk type IA EL in a polymorbid 68-year-old patient 7 years after primary EVAR. The principle of treatment was parallel implantation of the proximal SG extension with the renal SG into the right renal artery (chimney technique). The subsequent type II collateral EL was treated by direct transabdominal AAA sac puncture and thrombin embolization. Conclusion EL can be a cause for urgent intervention, but specific anatomic features often require specialized SG types which are not readily available. The chimney technique allows the use of immediately available stent grafts to address endoleak in the setting of impending abdominal aneurysm rupture.
- 4 April 2023
- Published by Springer Nature in Research Square
Open AccessComplex Endoleak Treatment After Failed Endovascular Aortic Repair
Background Endovascular aneurysm repair (EVAR) has created new possibilities for patients with abdominal aortic aneurysms (AAAs), and in recent years it has become tremendously popular. Use of EVAR in selected groups of patients allows mortality and morbidity to be reduced in comparison to open repair. However, complications such as endoleaks (ELs) can be of great concern and warrant urgent therapy to prevent sac rupture. Case Presentation The case report presents urgent endovascular treatment of a high-risk type IA EL in a polymorbid 68-year-old patient 7 years after primary EVAR. The principle of treatment was parallel implantation of the proximal SG extension with the renal SG into the right renal artery (chimney technique). The subsequent type II collateral EL was treated by direct transabdominal AAA sac puncture and thrombin embolization. Conclusion EL can be a cause for urgent intervention, but specific anatomic features often require specialized SG types which are not readily available. The chimney technique allows the use of immediately available stent grafts to address endoleak in the setting of impending abdominal aneurysm rupture.
- Open Access
- 6 December 2022
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 68 (8) , 508-512
Evolution of deep vein thrombosis treatment from leeches to mechanical thrombectomy
Hlubok? ?iln? tromb?za (DVT) pat?? v rozvinut?ch zem?ch k nej?ast?j??m onemocn?n?m s v?znamn?mi socioekonomick?mi dopady. Z?va?nost DVT spo??v? v mo?nosti vzniku ?ivot ohro?uj?c? plicn? embolie a k rozvoji chronick? ?iln? insuficience ozna?ova... Hlubok? ?iln? tromb?za (DVT) pat?? v rozvinut?ch zem?ch k nej?ast?j??m onemocn?n?m s v?znamn?mi socioekonomick?mi dopady. Z?va?nost DVT spo??v? v mo?nosti vzniku ?ivot ohro?uj?c? plicn? embolie a k rozvoji chronick? ?iln? insuficience ozna?ova...
- 6 December 2022
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 68 (8) , 508-512
Open AccessEvolution of deep vein thrombosis treatment from leeches to mechanical thrombectomy
Hlubok? ?iln? tromb?za (DVT) pat?? v rozvinut?ch zem?ch k nej?ast?j??m onemocn?n?m s v?znamn?mi socioekonomick?mi dopady. Z?va?nost DVT spo??v? v mo?nosti vzniku ?ivot ohro?uj?c? plicn? embolie a k rozvoji chronick? ?iln? insuficience ozna?ova... Hlubok? ?iln? tromb?za (DVT) pat?? v rozvinut?ch zem?ch k nej?ast?j??m onemocn?n?m s v?znamn?mi socioekonomick?mi dopady. Z?va?nost DVT spo??v? v mo?nosti vzniku ?ivot ohro?uj?c? plicn? embolie a k rozvoji chronick? ?iln? insuficience ozna?ova...